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Summary
Objective: This study was conducted to clarify whether the brachial-ankle pulse
wave velocity (baPWV) might serve as a marker of target organ damage in middle-
aged hypertensive subjects.
Methods and results: Multivariate linear regression analysis demonstrated that while
the baPWV showed a signiﬁcant relationship to the intima-media thickness of the
carotid artery (IMT), no such relationship was observed between the baPWV and
the left ventricular mass index as assessed by echocardiography or the estimated
glomerular ﬁltration rate in either the 162 hypertensive patients who had never
previously received antihypertensive medication or the 269 hypertensive patients
who were under antihypertensive medication for at least 1 year. Receiver—operator
characteristic (ROC) curve analysis suggested that a baPWV= 18m/s was the best
cutoff value to identify increased IMT in hypertensive patients who had never previ-
ously received antihypertensive medication (area under curve = 0.77). Binary logistic
regression analysis demonstrated that the odds ratio (OR) of a baPWV of ≥18m/s
for identifying increased IMT {OR= 7.38 (1.94—28.05)} was signiﬁcant, even after
adjustments. In hypertensive patients who had been under antihypertensive med-
ication for at least 1 year, however, the area under the curve and OR were only
modest.
ge of Cardiology. Published by Elsevier Ireland Ltd. All rights© 2008 Japanese Colle
reserved.
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Conclusion: The baPWV may be a marker of carotid atherosclerosis, rather than of
left ventricular hypertrophy or renal insufﬁciency, especially in middle-aged hyper-
tensive subjects (subjects in their 30s to 60s), not only in those who have never
previously received antihypertensive medication, but also in those who are under
antihypertensive medication.
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method [14]. The left ventricular mass index (LVMI)
was calculated as the left ventricular mass divided© 2008 Japanese Colleg
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Introduction
Recent studies have demonstrated that increased
arterial stiffness is an independent risk factor
for cardiovascular disease [1—5]. In Japan, the
brachial-ankle pulse wave velocity (baPWV) is
frequently used as a marker of arterial stiffness
[6,7]. However, it has not yet been clariﬁed
whether baPWV might also be a marker of subclin-
ical organ damage. Left ventricular hypertrophy
(LVH), increased intima-media thickness (IMT) of
the common carotid artery, and low estimated
glomerular ﬁltration rate (eGFR) are recognized
as signs of subclinical target organ damage in
hypertension [8—10]. The present cross-sectional
study was conducted to clarify whether the baPWV
might serve as a marker of subclinical target organ
damage (i.e., LVH, increased IMT of the common
carotid artery, and/or low eGFR) in middle-aged
hypertensive subjects. With this objective, we
attempted to evaluate the associations separately
in hypertensive subjects who had never previously
received antihypertensive medication and those
who had been on antihypertensive medication for
at least 1 year, because blood pressure is one of
the major determinants of the baPWV [11].
Methods
Subjects and protocol
From September 2001 to June 2007, 431 consec-
utive middle-aged subjects (in their 30s to 60s)
with hypertension (of which 162 had never previ-
ously received antihypertensivemedication and 269
consecutive hypertensive subjects who had been
under treatment with antihypertensive medication
for at least a year) who were seen at the out-
patient department of Tokyo Medical University
Hospital were enrolled in this study. Informed con-
sent was obtained from all of the participants. None
of the subjects had a history of atherosclerotic
cardiovascular diseases, including of symptoms or
electrocardiographic evidence of ischemic heart
disease, or of arrhythmias. Patients with seri-
ous medical problems requiring speciﬁc medical
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reatment were excluded from this study. Further-
ore, subjects meeting the following exclusion
riteria were also excluded an ankle/brachial sys-
olic blood pressure index (ABI) of less than 0.95,
trial ﬁbrillation and serum creatinine ≥2.0mg/dl
6,7,12]. Blood pressure was measured at the out-
atient clinic by the conventional cuff method.
easurement of the baPWV, echocardiography,
ltrasonography of the carotid artery, and blood
ampling were performed in the morning after the
ubjects had fasted overnight for 12 h. The study
rotocol was approved by the Ethics Committee of
okyo Medical University.
ulse wave velocity
he baPWV was measured using a volume-
lethymographic apparatus (Form/ABI, Colin, Co.
td., Komaki, Aichi, Japan). Details of the method-
logy have been described elsewhere [6,7,12,13].
n brief, the subjects were examined while resting
n the supine position. Electrocardiographic elec-
rodes were attached to both wrists, and cuffs were
rapped around both upper arms and ankles. The
ulse-volume waveform in the upper arm and ankle
ere recorded using a semiconductor pressure sen-
or after the subject had rested for at least 5min.
his method has been validated previously [6]. Usu-
lly, the brachial-ankle PWV is represented in the
nit of cm/s. In this study, however, the unit was
hanged to m/s to simplify determination of the
utoff value of the brachial-ankle PWV. Then, the
easured value was rounded off to the nearest 1000
i.e., 1500—1599 cm/s was represented as 15m/s).
ltrasonographic examination of the heart
nd carotid arteries
he left ventricular mass was calculated by
ransthorachic echocardiography by Devereux’sy the body surface area. After the echocardio-
raphic examination, both carotid arteries were
maged using an ultrasonographic system equipped
ith a 10.0-MHz transducer. The inter-observer
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Table 1 Clinical characteristics of the hypertensive subjects who had never previously received antihypertensive
medication and subjects who had received antihypertensive medication for at least a year
Never-treated Medication p-Value
Number of subjects 162 269
Age (years) 56± 10 60± 10 p < 0.01
Gender (male/female) 93/69 157/112 ns
BMI (kg/m2) 23.8± 3.8 24.0± 3.3 ns
Smoking (number of subjects) 36 73 ns
SBP (mmHg) 148± 19 130± 14 p < 0.01
DBP (mmHg) 88± 12 77± 9 p < 0.01
baPWV (m/s) 16.5± 3.6 15.5± 3.1 p < 0.01
LDL (mg/dl) 124± 27 119± 28 p < 0.01
HDL (mg/dl) 59± 15 54± 24 ns
TG (mg/dl) 115± 67 126± 67 ns
FPG (mg/dl) 107± 23 105± 12 ns
LVMI (g/m2) 120± 23 121± 27 ns
LVH (%) 90 (55.5) 123 (45.7) p < 0.05
IMT (mm) 0.80± 0.14 0.83± 0.16 ns
IMT > 0.9mm (%) 24 (14.8) 67 (24.9) p < 0.01
eGFR (ml/min/1.73m2) 76± 19 74± 20 ns
eGFR < 60ml/min/1.73m2 (%) 24 (14.8) 62 (23.0) p < 0.01
Medication
CCA 0 191 —
ARB 0 137 —
ACEi 0 28 —
BB 0 39 —
Diuretic 0 54 —
Statin 0 30 —
Oral anti-diabetics 0 4 —
Abbreviations: never-treated = hypertensive subjects who had never previously received antihypertensive medication; med-
ication = hypertensive subjects who had received antihypertensive medication for at least a year; BMI = body mass index;
SBP = systolic blood pressure; DBP = diastolic blood pressure; baPWV=brachial-ankle pulse wave velocity; LDL = serum low-density
lipoprotein cholesterol; HDL = serum high-density lipoprotein cholesterol; TG = serum triglycerides; FPG= fasting plasma glucose;
LVMI = left ventricular mass index; LVH= number of subjects with left ventricular hypertrophy; IMT = intima-media thickness of the
common carotid artery as assessed by ultrasound examination; IMT > 0.9mm=number of subjects with increased intima-media
thickness of the common carotid artery; eGFR = estimated glomerular ﬁltration rate; eGFR < 60ml/min/1.73m2 = number of
subjects with renal insufﬁciency; CCA = number of subjects prescribed a calcium channel antagonist; ARB = number of subjects
prescribed an angiotensin II receptor blocker; ACEi = number of subjects prescribed an angiotensin converting enzyme inhibitor;
mbe
escri
a
m
i
l
p
s
i
s
s
a
l
i
m
m
i
v
i
L
T
c
t
m
ples were obtained after the subjectsBB = number of subjects prescribed a beta-blocker; diuretic = nu
prescribed a statin; oral anti-diabetics = number of subjects pr
nd intra-observer coefﬁcients of variation for the
easurement of the left ventricular mass at our
nstitute were 7.2% and 13.5% [15].
Using guided two-dimensional ultrasonography,
ongitudinal B-mode images, approximately 1 cm
roximal to the carotid sinus, were obtained with
imultaneous electrocardiographic recordings. The
ntima-media thickness (IMT) was measured at a
ite free of any discrete plaques along a 10mm-long
egment of the far wall of the common carotid
rtery and measured as the distance between the
umen-intima interface and the media—adventitia
nterface at two points in the right and left com-
on carotid arteries. The means of these four
easurements were used for the analysis. The
nter-observer and intra-observer coefﬁcients of
h
m
d
0
(r of subjects prescribed a diuretic; statin = number of subjects
bed oral anti-diabetic medication.
ariation for the measurement of the IMT at our
nstitute were 6.2% and 6.0%.
aboratory measurements
he plasma levels of high-density lipoprotein
holesterol (HDL), low-density lipoprotein choles-
erol (LDL), triglycerides (TG) and glucose were
easured enzymatically. All blood sam-ad fasted overnight. The eGFR was esti-
ated using the modiﬁed modiﬁcation of
iet in renal disease (MDRD) equation; i.e.,
.741× 175× serumcreatinine−1.154 × age−0.203
×0.724 in female) [16].
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Table 2 Results of univariate linear regression analysis to assess the relationship of the brachial-ankle pulse wave
velocity to the parameters of target organ damage in the entire study population, in subjects who had never pre-
viously received antihypertensive medication and in subjects who had been under treatment with antihypertensive
medication for at least a year
Variable r p-Value
Entire study population (n = 431)
IMT 0.28 <0.01
LVMI 0.13 <0.01
eGFR −0.21 <0.01
Never received antihypertensive medication (n = 162)
IMT 0.38 <0.01
LVMI 0.22 <0.01
eGFR −0.19 0.02
Under treatment with antihypertensive medication for at least a year (n = 269)
IMT 0.25 <0.01
LVMI 0.08 0.20
eGFR −0.24 <0.01
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bAbbreviations: IMT = intima-media thickness of the common
ventricular mass index; eGFR = estimated glomerular ﬁltration
Statistics
Data were expressed as mean± S.D. Statistical
analysis was performed using the SPSS software
for Windows, Version 11.0J (SPSS, Chicago, IL). For
assessment of the differences between groups, an
un-paired t-test was applied for continuous vari-
ables, and the Chi-square test was applied for
categorical variables. Univariate linear regression
analysis was performed to evaluate the association
between the brachial-ankle PWV and other clini-
cal variables. Multivariate linear regression analysis
was applied to evaluate whether the relationships
between the brachial-ankle PWV and other parame-
ters of organ damage were independent from other
related factors. A receiver—operating characteris-
tic (ROC) curve was used to discriminate patients
with target organ damage based on the value of
the brachial-ankle PWV. Then, the value with the
highest sum of sensitivity + speciﬁcity was identiﬁed
as the cutoff value. Using these cutoff values, the
odds ratios for the presence of target organ dam-
age were calculated by binary logistic regression
analysis with and without adjustments.
Results
The clinical characteristics of the hypertensive
subjects who had never previously received anti-
hypertensive medication and the subjects who
had been under treatment with antihypertensive
medication for at least a year are shown in
Table 1. We deﬁned target organ damage as fol-
a
d
p
Hid artery as assessed by ultrasound examination; LVMI = left
ows: LVH:LVMI≥ 125 g/m2 in males and ≥110 g/m2
n females; increased IMT:IMT > 0.9mm; renal insuf-
ciency:eGFR < 60ml/min/1.73m2. The mean age
as higher and the blood pressure and baPWV were
ower in the subjects who had never previously
eceived antihypertensive medication than in the
ubjects who had been under treatment with anti-
ypertensive medication for at least a year. While
he LVMI, IMT and eGFR were similar in both groups,
he prevalence rates of LVH, increased IMT and
enal insufﬁciency were higher in the latter group
han in the former group (Table 1).
Univariate linear regression analysis demon-
trated signiﬁcant correlations between the
rachial-ankle PWV and the IMT, LVMI and eGFR in
ach of the entire study population, subjects who
ad never previously received antihypertensive
edication and the subjects who had been under
reatment with antihypertensive medication for at
east a year (Table 2). Multivariate linear regression
nalysis demonstrated a signiﬁcant relationship of
he brachial-ankle PWV to the IMT, but not to the
VMI or eGFR, after the adjustments using Model 1
adjusted for age, gender, body mass index, systolic
nd diastolic blood pressure, smoking status and
he plasma levels of LDL, HDL, TG and glucose) in
he group of subjects who had never previously
eceived antihypertensive medication (Table 3).
t also demonstrated a signiﬁcant relationship
etween the brachial-ankle PWV and IMT after
djustment using Model 2 [adjusted for age, gen-
er, body mass index, systolic and diastolic blood
ressure, smoking status, plasma levels of LDL,
DL, TG and glucose and medication {for diabetes
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Table 3 Results of multivariate linear regression analysis with adjustments to assess the relationship of the
brachial-ankle pulse wave velocity to the parameters of target organ damage in the entire study population, in
subjects who had never previously received antihypertensive medication and in subjects who had been under
treatment with antihypertensive medication for at least a year
Variable R2 Beta t-Value p-Value
Entire study population (n = 431)
IMT 0.21 0.15 2.39 <0.01
LVMI 0.18 0.09 1.39 0.17
eGFR 0.14 −0.06 −1.01 0.32
Adjusted using Model 2 (see text)
Never previously received antihypertensive medication (n = 162)
IMT 0.29 0.16 1.81 0.04
LVMI 0.27 0.12 1.24 0.22
eGFR 0.13 −0.17 −1.56 0.12
Adjusted using Model 1 (see text)
Under treatment with antihypertensive medication for at least a year (n = 269)
IMT 0.24 0.11 2.14 0.04
LVMI 0.21 0.07 1.03 0.30
eGFR 0.15 −0.06 −0.86 0.39
Adjusted using Model 2 (see text)
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eAbbreviations: IMT = intima-media thickness of the common
ventricular mass index; eGFR = estimated glomerular ﬁltration
ellitus, hypercholesterolemia and/or hyperten-
ion (calcium channel antagonist, angiotensin II
eceptor blocker, angiotensin converting enzyme
nhibitor, beta-blocker and diuretic)}] in the entire
tudy population and the subjects who had been
nder treatment with antihypertensive medication
or at least a year (Table 3).
Fig. 1 shows the ROC curve of the brachial-
nkle PWV to identify subjects with increased IMT in
he entire study population, the subjects who had
ever previously received antihypertensive med-
cation, and the subjects who had been under
reatment with antihypertensive medication for at
east a year. The best cutoff points were as follows:
ntire study population (area under curve = 0.68):
rachial-ankle PWV= 17m/s, sensitivity = 57% and
peciﬁcity = 70%; subjects who had never previously
eceived antihypertensive medication (area under
urve = 0.77): brachial-ankle PWV= 18m/s, sensi-
ivity = 75% and speciﬁcity = 74%; subjects who had
een under treatment with antihypertensive medi-
ation for at least a year (area under curve = 0.66):
rachial-ankle PWV= 16m/s, sensitivity = 63% and
peciﬁcity = 64%.
The results of a binary logistic regression analy-
is demonstrated that the odds ratio of the cutoff
alue of the brachial-ankle PWV for identifying
ncreased IMT was signiﬁcant in the subjects who
ad never previously received antihypertensive
edication adjusted using Model 1 and in the entire
tudy population and the subjects who had been
r
m
p
l
iid artery as assessed by ultrasound examination; LVMI = left
nder treatment with antihypertensive medication
or at least a year adjusted using Model 2 (Table 4).
he highest odds ratio was found for the subjects
hat had never previously received antihyperten-
ive medication (Table 4).
iscussion
therosclerotic plaques play a key role in the onset
f cardiovascular events [17]. The IMT reﬂects
he severity of the atherosclerotic changes in the
ommon carotid artery and is known as a use-
ul parameter to predict future cardiovascular
vents [9,18]. Arterial endothelial damage causes
laque formation, and abnormalities of the arte-
ial medial layer are thought to be a major
eterminant of increased arterial stiffness [1—5].
rogression of atherosclerosis produces abnormal-
ties of the arterial medial layer (i.e., vascular
mooth muscle hypertrophy and its proliferation
nd proliferation of connective tissue), and con-
ributes, at least in part, to further increase
f the arterial stiffness. In turn, increased arte-
ial stiffness enhances atherogenicity via disturbed
ndothelial shear stress [1—3]. Thus, atheroscle-
osis and increased arterial stiffness have a
utual cause—consequence relationship. In the
resent study, the results of the multivariate
inear regression analysis demonstrated a signif-
cant relationship of the brachial-ankle PWV to
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Figure 1 Receiver—operator characteristic curve between brachial-ankle pulse wave velocity and increased intima-
media thickness of the common carotid artery in the entire study population, in the group of subjects who had never
previously received antihypertensive medication, and in the group of subjects who had received antihypertensive
medication for at least a year. Abbreviations: whole = entire study population; never-treated = hypertensive subjects
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pwho had never previously received antihypertensive medi
antihypertensive medication for at least a year; arrow
curve.
the IMT, independent of confounding variables,
in not only hypertensive subjects who had never
previously received antihypertensive medication,
but also in those who had been under treatment
with antihypertensive medication for at least a
year.
Taking into consideration the results of the
ROC curve analysis and binary logistic regres-
sion analysis in this study, the brachial-ankle
PWV= 18m/s seemed to be an appropriate cutoff
value to identify increased IMT of the common
carotid artery in hypertensive subjects who had
never previously received antihypertensive med-
ication. Based on the results of this study, it
is proposed that a brachial-ankle PWV= 16m/s
M
t
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a
Table 4 Results of binary logistic regression analysis to i
carotid artery by the cutoff value of the brachial-ankle pul
entire study population, in subjects who had never previousl
who had been under treatment with antihypertensive medic
OR 95% CI
Entire study population (cutoff value of the baPWV ≥17m/s
Crude 3.11 1.93—5.0
Adjusted 2.33 1.2—4.4
Adjusted using Model 2 (see text)
Never previously received antihypertensive medication (cut
Crude 8.49 3.13—23.
Adjusted 7.38 1.94—28.
Adjusted using Model 1 (see text)
Under treatment with antihypertensive medication for at le
Crude 2.97 1.68—5.2
Adjusted 2.02 1.00—4.3
Adjusted using Model 2 (see text)
Abbreviations: OR = odds ratio; CI = conﬁdential interval; baPWV=bn; medication = hypertensive subjects who had received
esents the best discriminating point; AUC = area under
ight be a suitable cutoff value to identify
esidual carotid atherosclerosis in hypertensive
atients under antihypertensive treatment. How-
ver, the area under the curve in the ROC
nalysis was not large and the odds ratio to
dentify increased IMT was not sufﬁciently high.
herefore, the usefulness of the cutoff value
ay only be modest in patients under treat-
ent.
The European Society of Hypertension and Euro-
ean Society of Cardiology 2007 Guidelines for the
anagement of Arterial Hypertension has proposed
hat the PWV be also considered as one of the
arkers of subclinical target organ damage, and
threshold of the carotid—femoral PWV (cfPWV)
dentify increased intima-media thickness of common
se wave velocity with and without adjustments in the
y received antihypertensive medication and in subjects
ation for at least a year
p-Value
: n = 431)
1 <0.01
2 0.01
off value of the baPWV≥ 18m/s: n = 162)
06 <0.01
05 <0.01
ast a year (cutoff value of the baPWV≥ 16m/s: n = 269)
6 <0.01
7 0.05
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f >12m/s as a conservative estimate of signiﬁcant
lterations of aortic function [10]. The next logi-
al step would be to conﬁrm the threshold value
f the brachial-ankle PWV to predict future cardio-
ascular events by conducting prospective studies
n patients with hypertension.
Increased arterial stiffness causes LVH via
ncreased cardiac afterload and impairment of
GFR via microvascular damage via increased pulse
ressure [1,19,20]. After the adjustments, the
rachial-ankle PWV showed no signiﬁcant associ-
tion with the LVMI or eGFR in this study. The
bsences of these associations might be partially
xplained as follows. While central blood pressure
stimated by the augmentation index has been
eported to be closely correlated with the LVMI [21],
he PWV does not show a close correlation with this
ndex [22]. Thus, PWV is not a direct marker of the
ardiac afterload. The eGFR in 78—85% of the study
ubjects in this study was over 60ml/min/1.73m2.
he MDRD equation underestimates the eGFR in this
ange [23], and such underestimation might have
ontributed, at least in part, to the blunting of
he association of the brachial-ankle PWV with the
GFR.
tudy limitations
his study had two major limitations, as fol-
ows: ﬁrstly, in addition to blood pressure, age
s also a major determinant of arterial stiffness
11]. In our previous study subjects, age showed
closer correlation with the brachial-ankle PWV
r = 0.59, p < 0.01) than the systolic blood pres-
ure (r = 0.42, p < 0.01) or diastolic blood pressure
r = 0.41, p < 0.01) [24]. In the present study, we
ave proposed the target brachial-ankle PWVs for
ypertensive patients in their 30s to 60s, and
he mean age of the subjects in the present
tudy was 55 years. Therefore, the usefulness
f the brachial-ankle PWV as a marker of sub-
linical organ damage in hypertensive patients
ged 70 years or older should be examined. Sec-
ndly, microalbuminuria is another marker of target
rgan damage [10], but was not examined in this
tudy.
In conclusion, the brachial-ankle PWV may not
e a useful marker to identify LVH and/or low eGFR
n subjects with hypertension. On the other hand,
he parameter seems to reliably reﬂect the severity
f carotid atherosclerosis in middle-aged subjects
in their 30s to 60s) who have never previously
eceived antihypertensive medication rather than
n those who are under antihypertensive medica-
ion.
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